Danske Bank A S boosted its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 54.0% during the third quarter, HoldingsChannel reports. The fund owned 89,041 shares of the life sciences company’s stock after buying an additional 31,232 shares during the period. Danske Bank A S’s holdings in Illumina were worth $24,369,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in ILMN. Allworth Financial LP lifted its stake in shares of Illumina by 2.7% in the 3rd quarter. Allworth Financial LP now owns 6,139 shares of the life sciences company’s stock valued at $1,680,000 after purchasing an additional 163 shares during the last quarter. Altar Rock LLC purchased a new position in shares of Illumina during the 3rd quarter worth $248,000. Private Advisory Group LLC acquired a new stake in shares of Illumina during the 3rd quarter worth about $4,292,000. Legacy Trust increased its position in shares of Illumina by 1.1% during the 3rd quarter. Legacy Trust now owns 15,334 shares of the life sciences company’s stock worth $4,197,000 after purchasing an additional 164 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of Illumina by 8.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 232,646 shares of the life sciences company’s stock worth $63,651,000 after purchasing an additional 17,519 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.
Illumina Stock Performance
NASDAQ:ILMN opened at $198.00 on Tuesday. The company has a fifty day simple moving average of $248.62 and a two-hundred day simple moving average of $179.88. The company has a market cap of $29.94 billion, a price-to-earnings ratio of 34.08, a price-to-earnings-growth ratio of 2.84 and a beta of 1.46. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35.
Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.34 earnings per share. As a group, equities analysts anticipate that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have commented on ILMN shares. Evercore reaffirmed an “underperform” rating on shares of Illumina in a research report on Friday, October 30th. Weiss Ratings upgraded shares of Illumina from a “hold (c)” rating to a “buy (b-)” rating in a research report on Monday, November 2nd. Jefferies Financial Group set a $235.00 target price on Illumina and gave the company a “hold” rating in a research report on Monday. Barclays boosted their price target on shares of Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a research note on Wednesday, October 7th. Finally, Canaccord Genuity Group boosted their price target on shares of Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a research note on Monday, October 19th. Ten equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Illumina currently has an average rating of “Hold” and a consensus price target of $243.72.
Check Out Our Latest Stock Report on ILMN
Insider Buying and Selling
In other Illumina news, Director Keith Meister sold 299,336 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the sale, the director owned 1,409,851 shares in the company, valued at $307,291,123.96. This represents a 17.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 1,880,866 shares of company stock worth $415,708,114. Insiders own 2.90% of the company’s stock.
About Illumina
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
Featured Articles
- Five stocks we like better than Illumina
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
